BAFL 53.19 Increased By ▲ 3.16 (6.32%)
BIPL 22.90 Increased By ▲ 0.49 (2.19%)
BOP 5.67 Increased By ▲ 0.25 (4.61%)
CNERGY 5.12 Increased By ▲ 0.07 (1.39%)
DFML 19.35 Increased By ▲ 0.17 (0.89%)
DGKC 80.54 Increased By ▲ 0.39 (0.49%)
FABL 33.11 Increased By ▲ 0.26 (0.79%)
FCCL 20.25 No Change ▼ 0.00 (0%)
FFL 10.48 Increased By ▲ 0.83 (8.6%)
GGL 13.61 Increased By ▲ 0.01 (0.07%)
HBL 129.52 Increased By ▲ 8.18 (6.74%)
HUBC 123.38 Increased By ▲ 0.88 (0.72%)
HUMNL 8.04 Increased By ▲ 0.04 (0.5%)
KEL 4.43 Increased By ▲ 0.46 (11.59%)
LOTCHEM 28.01 Decreased By ▼ -0.07 (-0.25%)
MLCF 42.71 Increased By ▲ 0.51 (1.21%)
OGDC 125.38 Increased By ▲ 4.05 (3.34%)
PAEL 21.33 Increased By ▲ 1.10 (5.44%)
PIBTL 6.11 Increased By ▲ 0.31 (5.34%)
PIOC 118.47 Increased By ▲ 2.57 (2.22%)
PPL 113.85 Increased By ▲ 3.10 (2.8%)
PRL 31.80 Increased By ▲ 2.22 (7.51%)
SILK 1.10 Increased By ▲ 0.02 (1.85%)
SNGP 69.44 Increased By ▲ 0.41 (0.59%)
SSGC 13.76 Increased By ▲ 0.06 (0.44%)
TELE 9.16 Increased By ▲ 0.41 (4.69%)
TPLP 14.79 Increased By ▲ 0.12 (0.82%)
TRG 92.45 Increased By ▲ 1.15 (1.26%)
UNITY 27.47 Increased By ▲ 0.22 (0.81%)
WTL 1.67 Increased By ▲ 0.04 (2.45%)
BR100 6,815 Increased By 167.1 (2.51%)
BR30 24,245 Increased By 677 (2.87%)
KSE100 66,224 Increased By 1505.6 (2.33%)
KSE30 22,123 Increased By 529.1 (2.45%)
World

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron: study

  • Study was conducted by Humabs Biomed SA, a unit of Vir Biotechnology and the University of Washington, among others
Published December 17, 2021

COVID-19 vaccines from US drugmaker Johnson & Johnson and China's Sinopharm as well as Russia's Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.

The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.

Vaccines from Moderna, AstraZeneca and Pfizer and partner BioNTech retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.

WHO warns Covid variant Omicron risk ‘very high’

The study, conducted by Humabs Biomed SA, a unit of Vir Biotechnology and the University of Washington, among others, also found the decrease was less pronounced for vaccinated individuals who were previously infected.

The study also found that while the effectiveness of GlaxoSmithKline and Vir Biotech's COVID-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.

The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.

WHO sees unprecedented Omicron spread, 'probably' in most countries

In a real-world study published this week, it was seen that Pfizer-BioNTech's COVID-19 vaccine has been less effective in South Africa at keeping people infected with the virus out of hospital since the Omicron variant emerged last month.

Comments

Comments are closed.

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron: study

$100 billion export vision: Pakistan eyes to reduce trade deficit with China

Nawaz stresses on improving relations with India, other neigbours

Primary auction for GDS will also be held on PSX

Sukuk receives Rs479bn participation against Rs30bn target

Q1: Provinces’ budget surplus dips 76pc YoY

Gold price per tola falls Rs3,000 in Pakistan

Sarah Inam murder case: Verdict to be announced on December 14

Debt servicing: CPHGCL urges CPPA-G to make Rs25.4bn payment

OPEC members push against including fossil fuels phase-out in COP28 deal

Sydney bakes in hottest day in three years